Jade Biosciences JBIO
$15.31 +$0.25 (+1.66%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $15.31 0.00%
Open$15.00
Prev close$15.06
Day range$15.00 – $15.54
Volume1.02M
Market cap$1.06B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$39.64M-44.7% YoY
Net profit-$35.06M-39.2% YoY
Diluted EPS-$0.42+12.5% YoY
Free cash flow-$28.91M-30.3% YoY
Operating cash flow-$28.91M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Profitability & balance sheet
Return on equity-51.4%
Return on assets-47.4%
Return on invested capital-53.9%
Current ratio16.03
Liabilities / assets6.4%
Cash & investments$475.71M
Total debt$594,000.00
Net cash (debt)$475.11M
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| Net cash flow from investing | -$42.30M | -$97.63M | -$8.47M | -$98.16M | -$247.01M |
| -Change in Other Current Liabilities | -$30,000.00 | -$30,000.00 | -$29,000.00 | -$28,000.00 | $40,000.00 |
| -Change in Payables and Accrued Expense | -$651,000.00 | $1.69M | $3.93M | -$274,000.00 | $3.77M |
| -Change in Prepaid Assets | $191,000.00 | -$2.83M | $5.44M | -$10.20M | -$11.97M |
| Change in Working Capital | -$490,000.00 | -$1.17M | $9.34M | -$10.54M | -$8.20M |
| Other Non-Cash Items | $27,000.00 | $25,000.00 | $26,000.00 | $26,000.00 | $21.67M |
| Depreciation & Depletion & Amortization | $16,000.00 | $9,000.00 | $9,000.00 | $9,000.00 | $26,000.00 |
| Net Income from Continuing Operations | -$35.06M | -$55.77M | -$40.37M | -$31.93M | -$127.41M |
| Net cash flow from continuing operations | -$28.91M | -$43.66M | -$24.08M | -$33.65M | -$94.69M |
| Operating Cash Flow | -$28.91M | -$43.66M | -$24.08M | -$33.65M | -$94.69M |
| Net Cash Flow from Continuing Investing Activities | -$42.30M | -$97.63M | -$8.47M | -$98.16M | -$247.01M |
| Net PPE Purchase and Sale | $0.00 | – | – | -$3,000.00 | -$196,000.00 |
| Beginning Cash Balance | $107.25M | $55.09M | $88.44M | $50.11M | $69.39M |
| Free Cash Flow | -$28.91M | -$43.66M | -$24.08M | -$33.65M | -$94.89M |
| Effect of Exchange Rate Changes | -$5,000.00 | -$70,000.00 | -$7,000.00 | -$17,000.00 | -$21,000.00 |
| Financing Cash Flow | $44.36M | $193.52M | -$795,000.00 | $170.16M | $360.77M |
| Net Cash Flow from Continuing Financing Activities | $44.36M | $193.52M | -$795,000.00 | $170.16M | $360.77M |
| Net Common Stock Issuance | $44.00M | – | – | -$1.34M | $189.11M |
| Proceeds from Stock Option Exercised | $360,000.00 | $2.12M | $45,000.00 | $384,000.00 | $384,000.00 |
| Net Other Financing Charges | $0.00 | $0.00 | -$840,000.00 | $171.12M | $171.27M |
| Ending Cash Balance | $80.39M | $107.25M | $55.09M | $88.44M | $88.44M |
| Net Change in Cash | -$26.86M | $52.24M | -$33.35M | $38.35M | $19.07M |
| Net Investment Purchase and Sale | -$42.30M | -$97.63M | -$8.47M | -$98.19M | -$246.78M |
| -Change in Other Current Assets | – | $0.00 | $0.00 | – | -$38,000.00 |
| Net Other Investing Changes | – | – | – | $28,000.00 | -$31,000.00 |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 ANNUAL |
|---|---|---|---|---|---|
| -Short Term Investments | $395.32M | $353.96M | $256.21M | $247.72M | $247.72M |
| Other Current Assets | $9.86M | $10.05M | $7.22M | $12.66M | $12.66M |
| Total Non-Current Assets | $830,000.00 | $862,000.00 | $916,000.00 | $965,000.00 | $965,000.00 |
| Net PPE | $761,000.00 | $793,000.00 | $847,000.00 | $896,000.00 | $896,000.00 |
| -Gross PPE | $761,000.00 | $793,000.00 | $847,000.00 | $896,000.00 | $896,000.00 |
| Other Non-Current Assets | $69,000.00 | $69,000.00 | $69,000.00 | $69,000.00 | $69,000.00 |
| Total Liabilities | $30.89M | $32.20M | $22.97M | $17.26M | $17.26M |
| Total Current Liabilities | $30.29M | $31.57M | $22.29M | $16.54M | $16.54M |
| Payables | $3.03M | $6.58M | $3.98M | $2.15M | $2.15M |
| -Accounts Payable | $3.03M | $6.58M | $3.98M | $2.15M | $2.15M |
| Current Accrued Expenses | $6.85M | $11.30M | $12.90M | $11.07M | $11.07M |
| -Cash and Cash Equivalents | $80.39M | $107.25M | $55.09M | $88.44M | $88.44M |
| Cash and Cash Equivalents & Short-Term Investments | $475.71M | $461.21M | $311.30M | $336.16M | $336.16M |
| Total Assets | $486.39M | $472.11M | $319.43M | $349.78M | $349.78M |
| Total Current Assets | $485.56M | $471.25M | $318.52M | $348.82M | $348.82M |
| Other Current Liabilities | $9.64M | $9.77M | $2.67M | – | – |
| Total Non-Current Liabilities | $594,000.00 | $628,000.00 | $679,000.00 | $724,000.00 | $724,000.00 |
| Long Term Debt and Capital Lease Obligation | $594,000.00 | $628,000.00 | $679,000.00 | $724,000.00 | $724,000.00 |
| -Long Term Capital Lease Obligation | $594,000.00 | $628,000.00 | $679,000.00 | $724,000.00 | $724,000.00 |
| Total Equity | $455.50M | $439.92M | $296.46M | $332.52M | $332.52M |
| Stockholders' Equity | $455.50M | $439.92M | $296.46M | $332.52M | $332.52M |
| Capital Stock | $9,000.00 | $8,000.00 | $7,000.00 | $7,000.00 | $7,000.00 |
| -Common Stock | $7,000.00 | $6,000.00 | $5,000.00 | $5,000.00 | $5,000.00 |
| -Preferred Stock | $2,000.00 | $2,000.00 | $2,000.00 | $2,000.00 | $2,000.00 |
| Additional Paid-In Capital | $763.14M | $711.09M | $511.55M | $506.77M | $506.77M |
| Retained Earnings | -$305.58M | -$270.52M | -$214.76M | -$174.39M | -$174.39M |
| Gains/Losses Not Affecting Retained Earnings | -$2.07M | -$660,000.00 | -$342,000.00 | $129,000.00 | $129,000.00 |
| Convertible preferred securities | – | – | – | $0.00 | $0.00 |
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Selling and Admin Expenses | $8.82M | $8.85M | $7.39M | $20.42M | $6.44M |
| Operating Profit | -$39.64M | -$58.92M | -$43.45M | -$113.54M | -$34.98M |
| Net Non-Operating Interest Income (Expense) | $4.63M | $3.23M | $3.10M | $7.78M | $3.09M |
| Non-Operating Interest Income | $4.63M | $3.23M | $3.10M | $7.78M | $3.09M |
| Other Income (Expense) | -$34,000.00 | -$62,000.00 | -$9,000.00 | -$21.59M | $20,000.00 |
| Other Non-Operating Income (Expenses) | -$34,000.00 | -$62,000.00 | -$9,000.00 | -$21.59M | $20,000.00 |
| Pretax Profit | -$35.05M | -$55.75M | -$40.35M | -$127.35M | -$31.87M |
| Tax | $10,000.00 | $15,000.00 | $16,000.00 | $58,000.00 | $58,000.00 |
| Net Profit | -$35.06M | -$55.77M | -$40.37M | -$127.41M | -$31.93M |
| Profit from Continuing Operations | -$35.06M | -$55.77M | -$40.37M | -$127.41M | -$31.93M |
| Net Income to Parent Company | -$35.06M | -$55.77M | -$40.37M | -$127.41M | -$31.93M |
| Net Income to Common Stockholders | -$35.06M | -$55.77M | -$40.37M | -$127.41M | -$31.93M |
| Basic EPS | -$0.42 | -$0.76 | -$0.57 | -$3.19 | -$0.65 |
| Research & Development | $30.82M | $50.07M | $36.05M | $93.12M | $28.54M |
| -General & Admin Expense | $8.82M | $8.85M | $7.39M | $20.42M | $6.44M |
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $39.64M | $58.92M | $43.45M | $113.54M | $34.98M |
| Diluted EPS | -$0.42 | -$0.76 | -$0.57 | -$3.19 | -$0.65 |
No comments yet — be the first to weigh in on JBIO.
Sign in to join the discussion.